Trials / Completed
CompletedNCT00692510
Drug Interaction Study Between AZD3480 and Cytochrome P450
A Phase I, Double Blind, Randomized, Two-Way Cross Over, Single- Centre Study in Healthy CYP2D6 Extensive Metabolizers and Poor Metabolizers to Investigate the Potential of AZD3480 to Inhibit Cytochrome P450 1A2, 2C19, 3A4, 2C8, 2B6 and UGT1A1 Activity
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to evaluate if AZD3480 inhibits Cytochrome P450 1A2, 2C19, 3A4, 2C8, 2B6 and UGT1A1 activity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD3480 | Capsule, oral, dose once daily, 7 days |
| DRUG | Placebo | Capsule, oral, dose once daily, 7 days |
| DRUG | Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin) | Cocktail mix which contains the following: CYP1A2 (Caffeine), CYP2B6 (Bupropion), CYP2C8 (Rosiglitazone), CYP2C19 (Omeprazole), CYP3A4 (Midazolam), UGT1A1 (Bilirubin) single dose of mix |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2008-09-01
- Completion
- 2008-09-01
- First posted
- 2008-06-06
- Last updated
- 2008-11-26
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT00692510. Inclusion in this directory is not an endorsement.